AmericasENPublic regulatory overview
United States (USA)
Market Overview Population: Approximately 335 million (2024), the world's third most populous country Healthcare system: Dual publicprivate structure — Medicare (adults 65+ and cer...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMACore / local basisFDA authorization is the local market-access basis and defines the primary pathway.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRLimited benefitCE status has limited formal value in this market.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditStrong benefitMDSAP can reduce duplicate QMS audit burden and may be accepted as a substitute or strong audit evidence.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingLimited benefitNMPA approval has limited formal value and should not be presented as a reduction trigger.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: United States (USA)
- Product line: Medical devices
- Regulator / source: Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory maturity: Exceptionally high — FDA's Center for Devices and Radiological Health (CDRH) is the world's most influential medical device regulatory authority. The regulatory framework is comprehensive and highly detailed, and technical standards are rigorous. The 510(k) premarket notification pathway is the most widely studied and referenced device clearance mechanism globally. FDA review processes are highly transparent, guidance documents are of high quality, and administrative timelines are governed by the Medical Device User Fee Act (MDUFA) agreements with Congress
- Key fees: Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 335 million (2024), the world's third most populous country
- Healthcare system: Dual public-private structure — Medicare (adults 65+ and certain disabled individuals) and Medicaid (low-income populations) cover approximately 40% of the population; employer-sponsored group insurance and individual commercial plans cover the majority of the remainder; approximately 8–9% of the population is uninsured
- Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
- Regulatory maturity: Exceptionally high — FDA's Center for Devices and Radiological Health (CDRH) is the world's most influential medical device regulatory authority. The regulatory framework is comprehensive and highly detailed, and technical standards are rigorous. The 510(k) premarket notification pathway is the most widely studied and referenced device clearance mechanism globally. FDA review processes are highly transparent, guidance documents are of high quality, and administrative timelines are governed by the Medical Device User Fee Act (MDUFA) agreements with Congress
Regulatory Authority
- Primary authority: FDA (Food and Drug Administration)
- Relevant center: CDRH (Center for Devices and Radiological Health); certain IVD products are subject to joint oversight by CDER and CDRH
- Official portal: https://www.fda.gov/medical-devices; electronic submission system: eSTAR (Electronic Submission Template and Resource); establishment registration system: FDA FURLS (Unified Registration and Listing System)
- Key regulations:
- Federal Food, Drug, and Cosmetic Act (FD&C Act, 1938, as amended)
- 21 CFR Parts 800–900 series
- 21 CFR Part 820 — Quality System Regulation (QSR) / Quality Management System Regulation (QMSR, updated 2024, closely aligned with ISO 13485)
- 21 CFR Part 801 — Labeling
- 21 CFR Part 803 — Medical Device Reporting (MDR, adverse event reporting)
- 21 CFR Part 807 — Establishment Registration and Device Listing
- 21 CFR Part 814 — Premarket Approval Applications (PMA)
- Safe Medical Devices Act 1990 (SMDA)
- Medical Device User Fee and Modernization Act (MDUFMA/MDUFA series)
Device Classification
| Classification | Risk Level | EU/Global Equivalent | Description |
|---|---|---|---|
| Class I | Low risk | EU Class I | General Controls only; approximately half of Class I products are 510(k)-exempt; examples: bandages, thermometers, non-sterile surgical gloves |
| Class II | Moderate risk | EU Class IIa / IIb | General Controls + Special Controls; 510(k) is the primary clearance pathway, covering approximately 90% of all device submissions; examples: X-ray machines, dialysis equipment, infusion pumps, most orthopedic consumables |
| Class III | High risk | EU Class III | General Controls + Premarket Approval (PMA); requires Valid Scientific Evidence of safety and effectiveness; examples: cardiac pacemakers, prosthetic heart valves, high-risk implants |
Classification determination: Product Code + Intended Use together determine classification and the applicable regulatory pathway. The FDA Product Classification Database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) is the authoritative reference. The same physical product may fall into different classifications depending on its intended use.
IVD note: In vitro diagnostic devices follow a separate classification logic and must additionally reference the classification rules under 21 CFR Parts 862–864; analytical performance standards and reference material requirements are more stringent.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.